department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Mektovi · pharmadog

pharmadog
drugs
Mektovi

drug

patient view →

binimetinib

Marketedupdated 2mo ago

by Array BioPharma Inc

Approved

community read0 votes

indications

investigational

NSCLC

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Mektovi

generic

binimetinib

indication

Metastatic Melanoma

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 11, 2026

96 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

Oct 18, 2033compositionUS 9562016
Oct 18, 2033method-of-use (U-2330)US 9598376
Oct 18, 2033method-of-use (U-2334)US 9980944
Jul 4, 2031method-of-use (U-3737)US 93144645.0y
Aug 27, 2030method-of-use (U-3737)US 100057614.1y
Aug 27, 2030method-of-use (U-2333)US 98502294.1y
Mar 13, 2027compositionUS 7777050249d

FDA exclusivities (1)

Oct 11, 2026I-928Indication (3y)96d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagMelanoma6 co-mentions · 1 sources
tagOncology1 co-mentions · 1 sources
drugBRAFTOVI1 co-mentions · 1 sources
drugencorafenib1 co-mentions · 1 sources

Trials studying binimetinib

phase1PF-07284892 in Participants With Advanced Solid Tumorsterminatedn=53
phase1A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.recruitingn=267
phase4Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinibwithdrawn
phase2Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Canceractive not recruitingn=145
—UK ENcorafenib and BInimetinib Real-world Study in Melanomaactive not recruitingn=50
phase1Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumorsterminatedn=91
phase4The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trialsrecruitingn=46
phase3A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanomaactive not recruitingn=257

more trials →